Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy.
about
Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndromePharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndromeClinical Features of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Other Connective Tissue DiseasesMovement and Other Neurodegenerative Syndromes in Patients with Systemic Rheumatic Diseases: A Case Series of 8 Patients and Review of the LiteratureDemyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF-α treatment? Case report and literature review.Optic neuritis associated with adalimumab in the treatment of uveitis.Neurological disorders and inflammatory bowel diseasesAdverse events in IBD: to stop or continue immune suppressant and biologic treatmentOculomotor nerve palsy associated with bortezomib in a patient with multiple myeloma: a case report.Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study.Immediate anti-tumor necrosis factor-alpha (etanercept) therapy enhances axonal regeneration after sciatic nerve crush.Optic neuritis occurring with anti-tumour necrosis factor alpha therapy.Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007A case report of adalimumab-associated optic neuritis.Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease.Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.Neurological complications of biologic therapy in psoriasis: a review.Occurrence of demyelinating diseases after anti-TNFα treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study.Miller Fisher syndrome: brief overview and update with a focus on electrophysiological findings.Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors.Beyond the joints: neurological involvement in rheumatoid arthritis.Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics.Peripheral neuropathies in rheumatic disease--a guide to diagnosis.Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review.Infectious and noninfectious triggers in Guillain-Barré syndrome.Inflammatory bowel disease and demyelination: more than just a coincidence?Drug-induced peripheral neuropathy.Bilateral diaphragmatic paralysis associated with the use of the tumor necrosis factor-alpha inhibitor adalimumab.Symptom management in inflammatory bowel disease.Adverse Events During Anti-TNFα Therapies in IBD (Excluding Infections and Malignancies): When to Stop, Continue, or Switch Therapies.The Effects of IGF-1 on TNF-α-Treated DRG Neurons by Modulating ATF3 and GAP-43 Expression via PI3K/Akt/S6K Signaling Pathway.Tumor necrosis factor-α in Guillain-Barré syndrome, friend or foe?Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions.Demyelinizing Neurological Disease after Treatment with Tumor Necrosis Factor-α Antagonists.Early predictors of Guillain-Barré syndrome in the life course of women.Visual Loss Induced by Adalimumab Used for Plaque Psoriasis.Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease.
P2860
Q24200916-8CD3B86C-D969-4FFD-B659-DD50B39CFDA1Q24235600-6111FD13-E831-4353-917C-C3479791EE66Q26773164-8FD79405-8ECF-4E3F-A22B-5B0FBCFC9871Q26801152-45052EB5-EBE3-472E-B1AE-B09D4A7E0212Q30647378-6F7F4683-1DD1-4D1A-8B55-4338E2863E92Q31165527-3ED274A2-41E3-483D-AAB3-C2726809A2E2Q33681462-3151F138-D9C1-48D7-873F-4E4A23A3FB08Q33958822-0C5F3DFA-32F9-4DEF-B391-745B9A88DFC7Q34073191-8629A3AC-E6D4-41C5-AC4B-8D2CB48DB9F2Q34321781-F0AD81F9-BD0E-40B7-97F8-33D40E6204AAQ34501045-E29EEC88-F127-45A7-8CC3-9F9A746B39A0Q35127388-6890F2F1-D27E-4702-980D-647D516BB8FCQ35776433-10A04597-5F93-405D-81C1-2C156DD3AECCQ35954593-27FC079B-1C8A-4E26-AF73-EA644B6010AFQ36160532-A39192A6-B407-4666-94FB-50F06C31D532Q36171750-858B3439-DE96-41B0-9050-9880D5923745Q36223187-EB5934B7-5EF4-41D3-9A66-FC6C2FBFAB23Q36830722-177B6EB4-6DD3-4F42-A92A-2D51D3715E88Q37223169-EF85F031-B0E5-4FBC-8343-E4AEC0BAF4A0Q37781282-E3054399-E32D-4BCD-962C-21A3351485D0Q37822506-39C7116F-6584-4421-9A0E-C940DF7EF679Q37883488-C0363DEB-0794-448A-87ED-541DDE1C00EAQ37911726-C263CDBE-D519-4D96-B1B7-C00C4EA4AA2FQ37935613-C482243E-A176-4C12-8E57-F382AED2C2A6Q38007126-6D020C1F-ABB3-4748-9F15-96B6D90A8401Q38036106-7C79C438-655F-4F8C-AACE-9C6318C6EB72Q38105939-CEB28182-F50F-41AB-ABD1-045D6B0B6A4DQ38125242-EE210BC0-46F9-43CE-B2BC-D7399CD39903Q38184633-359D5AE4-043F-419A-A6F1-22DBADCC1048Q38208565-8E7AAE58-C3FB-4347-A128-B1DD5B111FD8Q38275738-C5E1BE5A-5B3A-4530-8F49-E65F51560188Q38438128-4D7067C6-3DFD-4969-A0BD-5705AA228AAFQ38751610-F9D46646-1659-4BDD-B359-A14598B1F31FQ38955853-385A4ADA-C056-4F59-A638-B9029D19B585Q39000208-C7B5BC63-536D-4A4D-8043-F76104C8FA8FQ39157513-31796678-1E25-4A24-9E3D-5DD00742FAD2Q41934387-FE8C2C25-393B-4411-8309-581EA9FAE8C8Q41986460-9BEA00CA-96D5-4A9E-9890-51DD6DEC5DA0Q42210912-247F30B5-384B-46D2-B4A6-E092F00C82DAQ43132889-64F63FCE-61FB-45A9-9CD8-9BDB4300DB7A
P2860
Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Guillain-Barré and Miller Fish ...... ctor alpha antagonist therapy.
@ast
Guillain-Barré and Miller Fish ...... ctor alpha antagonist therapy.
@en
type
label
Guillain-Barré and Miller Fish ...... ctor alpha antagonist therapy.
@ast
Guillain-Barré and Miller Fish ...... ctor alpha antagonist therapy.
@en
prefLabel
Guillain-Barré and Miller Fish ...... ctor alpha antagonist therapy.
@ast
Guillain-Barré and Miller Fish ...... ctor alpha antagonist therapy.
@en
P2093
P356
P1476
Guillain-Barré and Miller Fish ...... ctor alpha antagonist therapy.
@en
P2093
Alan N Baer
Elektra J Papadopoulos
Hyon J Kwon
In-Sook J Shin
Jeffrey N Siegel
P2860
P304
P356
10.1002/ART.21814
P577
2006-05-01T00:00:00Z